Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 402 participants.
Also called NCT01140581
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 402 participants
- Sponsor
- Registry
-
NCT01140581 -
2009-016818-24
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, Austria, Estonia, Finland, France, Germany, Israel, Italy, Mexico, Netherlands, Portugal, South Korea, Spain, Switzerland, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01140581. Randomized; no masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2011-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation
- Acronym
- ARTEMIS Load
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- DRONEDARONE
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01140581- Content hash
0a78965d9707770e938cc12907bbffad8991d104c7e2b7c7eda891a06e6e1643